Logan Lutton

Melody Chang, RPh, BCOP, MBA, of the American Oncology Network, discusses building outpatient infrastructure for bispecific antibody and CAR-T therapy.

The Senate confirmed Erica Schwartz, M.D., J.D., M.P.H., 51-44, as CDC director, ending the agency's nearly year-long leadership vacancy.

A South African trial found a doravirine-based HIV regimen caused less weight gain than a dolutegravir-based combination.

In this discussion, Mahavir Agarwal, M.D., Ph.D., a psychiatrist and scientist in the Schizophrenia Division at the Centre for Addiction and Mental Health (CAMH) in Toronto and an associate professor in the Department of Psychiatry at the University of Toronto, discusses recent advancements in treating antipsychotic-associated weight gain.

As she moved from specialty operations into broader benefit leadership roles, McMahan says her perspective changed, and she began to see the "whole board."

Savasta welcomes the new transparency rules for pharmacy benefit managers because "transparency has always been a core component of our business model."

CMS said its Medicaid Fraud War Room suspended more than $203 million in improper payments and flagged 50 high-risk providers in its first 88 days of operation.

CMS has set the 2027 Part D bid amount at $296.05 and will end its premium stabilization demonstration, raising cost questions for 25 million enrollees.

Community-led programs across four countries show gains in HIV retention, mental health and service uptake among people who engage in chemsex.

Raphael J. Landovitz, M.D., of UCLA, says HIV prevention science has surged ahead of the world's ability to deliver it.

Raphael J. Landovitz, M.D., says rare lenacapavir breakthrough infections raise new questions about how often patients need testing between PrEP doses.

Raphael J. Landovitz, M.D., of UCLA says surveillance gaps, Medicaid nonexpansion states and injectable pricing are stalling U.S. PrEP uptake.

Real-world CAPTIVATE study of 241 CAB LA users found no HIV acquisitions, 99% satisfaction and 97% preference over oral PrEP.

Metformin, topiramate and three GLP-1 receptor agonists ranked as the most effective options for managing antipsychotic-induced weight gain, according to a new study published in JAMA Psychiatry.

Semaglutide cut body weight by more than 24 lbs versus placebo in antipsychotic-treated patients with schizophrenia, according to a recent study published in JAMA Psychiatry.

Edward Machtinger, M.D., of UCSF says most mental illness and substance use trace back to trauma, and clinics that ignore this can retraumatize patients.

Edward Machtinger, M.D., of UCSF says stigma often keeps women with HIV silent and isolated, discouraging care and disclosure to family and friends.

In this interview, Edward Machtinger, M.D., a professor of medicine at the University of California, San Francisco, director of the Center to Advance Trauma-Informed Healthcare and co-director of the Women's HIV Program, explains that many women with HIV actually die from issues like mental health problems, addiction, stigma, and violence rather than the virus itself, and he says we need better ways to capture these realities and provide more supportive, trauma-informed care.

In this discussion, Dolores Malaspina, M.D., a pharmacological sciences professor at the Icahn School of Medicine at Mount Sinai, explains how schizophrenia risk may be caused by trauma-alerted biological signaling, rather than genetics alone.

A retrospective study of 174,250 retina practice patients found that dismissals, though rare, disproportionately affected younger, lower-income patients with diabetic retinopathy, raising equity and continuity of care concerns.

A study in Advanced Functional Materials found that mRNA vaccine nanoparticles can survive drying and rehydration in microneedle patch material, offering a potential path toward vaccines that no longer require cold chain storage.

Specific brainstem inhibitory neurons help the brain filter out distractions by suppressing competing sensory signals, allowing mice (and presumably humans) to stay focused.

The FTC has settled its antitrust case against Caremark, requiring changes to drug pricing and rebate practices with up to $8.5 billion in potential consumer savings over the next 10 years.

In this conversation, Johns Hopkins researchers describe a newly identified population of brainstem neurons that are crucial for selective attention in mice and may offer fresh insight into ADHD in humans.

A former radiation oncologist turned chief medical officer, Rex Hoffman, M.D., MBA, has spent the past several years expanding his leadership footprint across Providence Holy Cross Medical Center’s health system while authoring multiple books aimed at helping physicians navigate the transition into executive roles.

A new study in JAMA Network Open projects that the number of Medicare beneficiaries 65 and older living with HIV will grow from approximately 122,000 to 194,000 by 2035, driving cumulative Medicare costs of $187.2 billion, with antiretroviral therapy alone accounting for 63% of that spending.

Marc Elia of Invyvid explains the difference between vaccines and monoclonal antibodies.

A phase 3b trial found that Otsuka's centanafadine significantly improved both ADHD symptoms and anxiety symptoms in adults with ADHD and comorbid anxiety, with effects emerging as early as week 1 and holding through 8 weeks, as the drug awaits an FDA decision expected July 24, 2026.

In this interview, Marc Elia argues that monoclonal antibodies like VYD2311 offer a fundamentally different approach to COVID-19 prevention than vaccines, delivering protective antibodies directly rather than triggering an immune response, which he says could improve tolerability.

Built from the experiences of patients, advocates and clinicians, a new MASH patient journey map offers a roadmap for navigating diagnosis and highlights the need for greater public understanding of the disease.